| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$124.1M | ROE | −49.53% |
| Net Margin | — | ROIC | −49.94% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $328.9M | Trading Days | 1359 |
| 52W High | 6.95 |
| 52W Low | 1.21 |
| % Off High | −33.53% |
| YTD | 242.22% | 1Y | 220.83% |
| 3Y | −82.72% | 5Y | −91.43% |
| Since incept. (ann.) | −31.67% |
| Ann. Volatility (1Y) | 131.00% | Ann. Volatility (3Y) | 108.42% |
| Sharpe (1Y) | 1.48 | Sharpe (3Y) | −0.01 |
| Max Drawdown (1Y) | −46.75% | Max Drawdown (3Y) | −96.32% |
| Beta (3Y, vs SPY) | 2.30 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CATX | Perspective Therapeutics, Inc. | $327.3M | — |
| CTNM | Contineum Therapeutics, Inc. | $327.1M | — |
| ORGO | Organogenesis Holdings Inc. | $325.5M | 16.9 |
| AKBA | Akebia Therapeutics, Inc. | $340.7M | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $342.9M | — |
| ABEO | ABEONA THERAPEUTICS INC. | $343.1M | 6.0 |
| UPB | Upstream Bio, Inc. | $348.3M | — |
| VNDA | Vanda Pharmaceuticals Inc. | $310.3M | — |
| LYEL | Lyell Immunopharma, Inc. | $303.1M | — |
| DMAC | DiaMedica Therapeutics Inc. | $357.8M | — |
| FHTX | Foghorn Therapeutics Inc. |
| $301.2M |
| — |
| AVIR | Atea Pharmaceuticals, Inc. | $360.9M | — |
